← 產業報告目錄

Soft Tissue Sarcoma Market Research Report Information By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others), By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery) By End Use (Hospitals and Clinics, Cancer Research Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest of the World) Industry Forecast Till 2032

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2025-05-02頁數 187報告編號 MRFRPharma3862HCR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

Soft Tissue Sarcoma Market Research Report Information By Diagnosis (Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others), By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery) By End Use (Hospitals and Clinics, Cancer Research Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest of the World) Industry Forecast Till 2032 Market Overview The Soft Tissue Sarcoma Market Size was estimated to be USD 3,248.52 Million in 2023 and is expected to increase to USD 6,204.02 Million by 2032, with a compound annual growth rate (CAGR) of 7.67% during the forecast period (2024-2032). The primary market drivers that contribute to market growth include the introduction of new products, the increased utilization of innovative therapies, and a broader target population. The introduction of new products, the prevalent use of innovative medicines, and an expansion of the target audience are among the key market drivers that are driving market growth. The discovery and development of novel therapeutics are significant factors that are driving the soft tissue sarcoma market. The availability of innovative medications and therapies for the treatment of soft tissue sarcoma has exploded in the past decade. The expanded treatment options and enhanced effectiveness that these groundbreaking pharmaceuticals enable are advantageous to both patients and physicians. Market segment insights Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST), and Others comprise the global soft tissue sarcoma market, which is segmented according to its type. The Gastrointestinal Stromal Tumor (GIST) segment is the fastest growing segment during the forecast period, while the Angiosarcoma segment held the largest market in 2023. The Global Soft Tissue Sarcoma Market has been segmented into Diagnosis and Treatment. The Diagnostic segment was the largest market in 2023, and the Treatment segment is the fastest-growing segment during the forecast period. The diagnosis is further divided into the following categories: Ultrasound Scan, Magnetic Resonance Imaging (MRI), Biopsy, and others, such as PET scan and X-ray. Targeted therapy, chemotherapy, radiation therapy, antiangiogenic drugs, and surgery comprise the treatment regimen. The Global Soft Tissue Sarcoma Market has been segmented into Hospitals and Clinics, Cancer Research Centers, and others based on End User. The Hospitals and Clinics segment is the fastest-growing segment during the forecast period and held the largest market in 2023. Regional Perspectives The study offers market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2022, the soft tissue sarcoma market was primarily dominated by North America, with Europe and the Asia-Pacific region following in that order. This is due to the high prevalence of soft tissue sarcoma in North America and Europe, as well as the presence of modern healthcare infrastructure and R&D activity in these regions. The European Soft Tissue Sarcoma market is the second greatest shareholder in the global market. In December 2021, the European Medicines Agency (EMA) granted conditional marketing authorization for Tazverik (tazemetostat) for the treatment of epithelioid sarcoma in adults. Additionally, the Asia Pacific Soft Tissue Sarcoma market is anticipated to experience the most rapid compound annual growth rate (CAGR) during the forecast period. In September 2021, the China National Medical Products Administration (NMPA) approved Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST), a type of soft tissue sarcoma. Major Players GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services Inc. (U.S.), and others are among the major players in the Soft Tissue Sarcoma market.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY .............................................................................................................. 20 2 MARKET INTRODUCTION ............................................................................................................ 22 2.1 DEFINITION .................................................................................................................................................................. 22 2.2 SCOPE OF THE STUDY .............................................................................................................................................. 22 2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 22 2.4 MARKET STRUCTURE .............................................................................................................................................. 22 3 RESEARCH METHODOLOGY ...................................................................................................... 23 3.1 OVERVIEW .................................................................................................................................................................... 23 3.2 DATA FLOW .................................................................................................................................................................. 25 3.2.1 DATA MINING PROCESS ................................................................................................................................. 25 3.3 PURCHASED DATABASE: ......................................................................................................................................... 26 3.4 SECONDARY SOURCES: ............................................................................................................................................ 27 3.4.1 SECONDARY RESEARCH DATA FLOW: ............................................................................................................. 28 3.5 PRIMARY RESEARCH: ............................................................................................................................................... 29 3.5.1 PRIMARY RESEARCH DATA FLOW: ................................................................................................................. 30 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 31 3.6.1 REVENUE ANALYSIS APPROACH ..................................................................................................................... 31 3.7 DATA FORECASTING................................................................................................................................................. 32 3.7.1 DATA FORECASTING TYPE .............................................................................................................................. 32 3.8 DATA MODELING ........................................................................................................................................................ 33 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............................................................................................................ 33 3.8.2 DATA MODELING: ........................................................................................................................................... 34 3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 36 4 MARKET DYNAMICS .................................................................................................................... 38 4.1 INTRODUCTION ........................................................................................................................................................... 38 4.2 DRIVERS ......................................................................................................................................................................... 39 4.2.1 INCREASING INCIDENCE OF SOFT TISSUE SARCOMAS ..................................................................................... 39 4.2.2 RISING AWARENESS ASSOCIATED WITH SOFT TISSUE SARCOMA .................................................................... 39 4.2.3 GROWING APPROVAL OF INNOVATIVE TREATMENT FOR SOFT TISSUE SARCOMA ............................................ 40 4.3 RESTRAINTS ................................................................................................................................................................ 42 4.3.1 SIDE-EFFECTS OF SOFT TISSUE SARCOMA DRUGS ........................................................................................... 42 4.3.2 VOLUNTARY PRODUCT RECALLS BY MARKET PLAYERS ................................................................................... 42 4.4 OPPORTUNITY ............................................................................................................................................................. 44 4.4.1 GROWING GERIATRIC POPULATION ................................................................................................................ 44 4.4.2 INVESTMENTS IN RESEARCH AND DEVELOPMENT .......................................................................................... 44 4.4.3 ONGOING CLINICAL TRIALS FOR SOFT TISSUE SARCOMA ................................................................................ 45 5 MARKET FACTOR ANALYSIS ...................................................................................................... 46 5.1 PORTER'S FIVE FORCES MODEL ........................................................................................................................... 46 5.1.1 THREAT OF NEW ENTRANTS ........................................................................................................................... 46 5.1.2 BARGAINING POWER OF SUPPLIERS ............................................................................................................... 47 5.1.3 THREAT OF SUBSTITUTES .............................................................................................................................. 47 5.1.4 BARGAINING POWER OF BUYERS .................................................................................................................... 47 5.1.5 INTENSITY OF RIVALRY .................................................................................................................................. 47 5.2 IMPACT OF COVID-19 ON GLOBAL SOFT TISSUE SARCOMA MARKET ................................................... 48 5.3 KEY MARKET TRENDS IN THE CHINA SOFT TISSUE SARCOMA MARKET ......................................... 49 5.4 TECHNOLOGICAL ADVANCEMENTS IN CHINA ............................................................................................... 50 5.5 REGULATORY FRAMEWORK IN CHINA ............................................................................................................. 52 5.6 PIPELINE ANALYSIS IN CHINA ............................................................................................................................. 53 5.7 AVERAGE PRICING OF PRODUCTS IN CHINA, 2023 ........................................................................................ 56 6 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE ............................................................. 58 6.1 OVERVIEW .................................................................................................................................................................... 58 6.2 ANGIOSARCOMA ........................................................................................................................................................ 60 6.3 EPITHELIOID SARCOMA .......................................................................................................................................... 61 6.4 GASTROINTESTINAL STROMAL TUMOR (GIST) ............................................................................................. 61 6.5 OTHERS .......................................................................................................................................................................... 62 7 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT ................... 63 7.1 OVERVIEW .................................................................................................................................................................... 63 7.2 DIAGNOSIS .................................................................................................................................................................... 65 7.2.1 BIOPSY .......................................................................................................................................................... 66 7.2.2 ULTRASOUND SCAN ....................................................................................................................................... 66 7.2.3 MAGNETIC RESONANCE IMAGING (MRI) ......................................................................................................... 67 7.2.4 OTHERS ......................................................................................................................................................... 67 7.3 TREATMENT................................................................................................................................................................ 68 7.3.1 TARGETED THERAPY ...................................................................................................................................... 69 7.3.2 CHEMOTHERAPY ............................................................................................................................................ 69 7.3.3 ANTI-ANGIOGENESIS DRUGS ..................................................................................................................... 70 7.3.4 RADIATION THERAPY ..................................................................................................................................... 70 7.3.5 SURGERY ....................................................................................................................................................... 71 8 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER .................................................... 72 8.1 OVERVIEW .................................................................................................................................................................... 72 8.2 HOSPITALS AND CLINICS ........................................................................................................................................ 74 8.3 CANCER RESEARCH CENTERS .............................................................................................................................. 75 8.4 OTHERS .......................................................................................................................................................................... 75 9 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION ........................................................ 76 9.1 OVERVIEW .................................................................................................................................................................... 76 9.2 NORTH AMERICA ....................................................................................................................................................... 77 9.2.1 US.................................................................................................................................................................. 81 9.2.2 CANADA ........................................................................................................................................................ 83 9.3 EUROPE .......................................................................................................................................................................... 85 9.3.1 GERMANY ...................................................................................................................................................... 89 9.3.2 FRANCE ......................................................................................................................................................... 91 9.3.3 UK ................................................................................................................................................................. 93 9.3.4 ITALY ............................................................................................................................................................. 95 9.3.5 SPAIN ............................................................................................................................................................ 97 9.3.6 RUSSIA .......................................................................................................................................................... 99 9.3.7 REST OF EUROPE ............................................................................................................................................ 101 9.4 ASIA-PACIFIC ............................................................................................................................................................... 103 9.4.1 CHINA ............................................................................................................................................................ 107 9.4.2 INDIA ............................................................................................................................................................. 109 9.4.3 JAPAN ........................................................................................................................................................... 111 9.4.4 SOUTH KOREA ................................................................................................................................................ 113 9.4.5 MALAYSIA ..................................................................................................................................................... 115 9.4.6 THAILAND ...................................................................................................................................................... 117 9.4.7 INDONESIA ..................................................................................................................................................... 119 9.4.8 REST OF ASIA-PACIFIC ................................................................................................................................... 121 9.5 SOUTH AMERICA ....................................................................................................................................................... 123 9.5.1 BRAZIL ........................................................................................................................................................... 127 9.5.2 MEXICO ......................................................................................................................................................... 129 9.5.3 ARGENTINA ................................................................................................................................................... 131 9.5.4 REST OF SOUTH AMERICA .............................................................................................................................. 133 9.6 MIDDLE EAST AND AFRICA .................................................................................................................................... 135 9.6.1 GCC COUNTRIES............................................................................................................................................. 139 9.6.2 SOUTH AFRICA ............................................................................................................................................... 142 9.6.3 REST OF MIDDLE EAST AND AFRICA ................................................................................................................ 144 10 COMPETITIVE LANDSCAPE ........................................................................................................ 148 10.1 INTRODUCTION ........................................................................................................................................................... 148 10.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 148 10.3 COMPETITOR DASHBOARD..................................................................................................................................... 149 10.4 PUBLIC PLAYERS STOCK SUMMARY ................................................................................................................. 150 10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL .............................................................................. 150 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 151 10.6.1 PRODUCT APPROVAL ..................................................................................................................................... 151 10.6.2 COLLABORATION ........................................................................................................................................... 151 10.6.3 PRODUCT LAUNCH ......................................................................................................................................... 151 11 COMPANY PROFILES .................................................................................................................. 152 11.1 GE HEALTHCARE ....................................................................................................................................................... 152 11.1.1 COMPANY OVERVIEW ..................................................................................................................................... 152 11.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 153 11.1.3 PRODUCTS/SERVICES OFFERED ...................................................................................................................... 154 11.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 154 11.1.5 SWOT ANALYSIS ............................................................................................................................................ 155 11.1.6 KEY STRATEGIES ............................................................................................................................................ 155 11.2 CANON MEDICAL SYSTEMS CORPORATION .................................................................................................... 156 11.2.1 COMPANY OVERVIEW ..................................................................................................................................... 156 11.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 157 11.2.3 PRODUCT OFFERED ........................................................................................................................................ 157 11.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 158 11.2.5 KEY STRATEGIES ............................................................................................................................................ 158 11.3 NOVARTIS AG .............................................................................................................................................................. 159 11.3.1 COMPANY OVERVIEW ..................................................................................................................................... 159 11.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 160 11.3.3 PRODUCTS OFFERED ...................................................................................................................................... 160 11.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 161 11.3.5 SWOT ANALYSIS ............................................................................................................................................ 161 11.3.6 KEY STRATEGIES ............................................................................................................................................ 161 11.4 F. HOFFMANN-LA ROCHE LTD. ............................................................................................................................. 163 11.4.1 COMPANY OVERVIEW ..................................................................................................................................... 163 11.4.2 FINANCIAL OVERVIEW .................................................................................................................................... 164 11.4.3 PRODUCTS OFFERED ...................................................................................................................................... 164 11.4.4 KEY DEVELOPMENTS ...................................................................................................................................... 164 11.4.5 SWOT ANALYSIS ............................................................................................................................................ 165 11.4.6 KEY STRATEGIES ............................................................................................................................................ 166 11.5 BLUEPRINT MEDICINES CORPORATION ............................................................................................................ 167 11.5.1 COMPANY OVERVIEW ..................................................................................................................................... 167 11.5.2 FINANCIAL OVERVIEW .................................................................................................................................... 168 11.5.3 PRODUCTS OFFERED ...................................................................................................................................... 168 11.5.4 KEY DEVELOPMENTS ...................................................................................................................................... 169 11.5.5 KEY STRATEGIES ............................................................................................................................................ 169 11.6 JOHNSON & JOHNSON INC. ..................................................................................................................................... 170 11.6.1 COMPANY OVERVIEW ..................................................................................................................................... 170 11.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 171 11.6.3 PRODUCTS OFFERED ...................................................................................................................................... 171 11.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 172 11.6.5 SWOT ANALYSIS ............................................................................................................................................ 172 11.6.6 KEY STRATEGIES ............................................................................................................................................ 172 11.7 BRISTOL-MYERS SQUIBB COMPANY .................................................................................................................. 173 11.7.1 COMPANY OVERVIEW .................................................................................................................................... 173 11.7.2 FINANCIAL OVERVIEW .................................................................................................................................... 174 11.7.3 PRODUCTS OFFERED ...................................................................................................................................... 174 11.7.4 KEY DEVELOPMENTS ...................................................................................................................................... 175 11.7.5 KEY STRATEGIES ............................................................................................................................................ 175 11.8 EISAI CO., LTD .............................................................................................................................................................. 176 11.8.1 COMPANY OVERVIEW ..................................................................................................................................... 176 11.8.2 FINANCIAL OVERVIEW .................................................................................................................................... 177 11.8.3 PRODUCTS OFFERED ...................................................................................................................................... 177 11.8.4 KEY DEVELOPMENTS ...................................................................................................................................... 177 11.8.5 SWOT ANALYSIS ............................................................................................................................................ 178 11.8.6 KEY STRATEGIES ............................................................................................................................................ 178 11.9 SIEMENS HEALTHINEERS ...................................................................................................................................... 179 11.9.1 COMPANY OVERVIEW ..................................................................................................................................... 179 11.9.2 FINANCIAL OVERVIEW .................................................................................................................................... 180 11.9.3 PRODUCTS OFFERED ...................................................................................................................................... 180 11.9.4 KEY DEVELOPMENTS ...................................................................................................................................... 181 11.9.5 SWOT ANALYSIS ............................................................................................................................................ 181 11.9.6 KEY STRATEGIES ............................................................................................................................................ 182 11.10 ELI LILLY AND COMPANY ....................................................................................................................................... 183 11.10.1 COMPANY OVERVIEW ..................................................................................................................................... 183 11.10.2 FINANCIAL OVERVIEW .................................................................................................................................... 184 11.10.3 PRODUCTS OFFERED ...................................................................................................................................... 184 11.10.4 KEY DEVELOPMENTS ...................................................................................................................................... 185 11.10.5 KEY STRATEGIES ............................................................................................................................................ 185 12 DATA CITATIONS ......................................................................................................................... 186
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 34 TABLE 2 PIPELINE ANALYSIS IN CHINA 53 TABLE 3 AVERAGE PRICIING OF PRODUCTS IN CHINA (IN USD), 2023 56 TABLE 4 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018–2032 (USD MILLION) 59 TABLE 5 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR ANGIOSARCOMA, BY REGION, 2018–2032 (USD MILLION) 60 TABLE 6 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR EPITHELIOID SARCOMA, BY REGION, 2018–2032 (USD MILLION) 61 TABLE 7 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR GASTROINTESTINAL STROMAL TUMOR (GIST), BY REGION, 2018–2032 (USD MILLION) 61 TABLE 8 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR OTHERS, BY REGION, 2018–2032 (USD MILLION) 62 TABLE 9 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT, 2018–2032 (USD MILLION) 64 TABLE 10 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY REGION, 2018–2032 (USD MILLION) 65 TABLE 11 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2032 (USD MILLION) 65 TABLE 12 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR BIOPSY, BY REGION, 2018–2032 (USD MILLION) 66 TABLE 13 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR ULTRASOUND SCAN, BY REGION, 2018–2032 (USD MILLION) 66 TABLE 14 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018–2032 (USD MILLION) 67 TABLE 15 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR OTHERS, BY REGION, 2018–2032 (USD MILLION) 67 TABLE 16 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY REGION, 2018–2032 (USD MILLION) 68 TABLE 17 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2032 (USD MILLION) 68 TABLE 18 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR TARGETED THERAPY, BY REGION, 2018–2032 (USD MILLION) 69 TABLE 19 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR CHEMOTHERAPY, BY REGION, 2018–2032 (USD MILLION) 69 TABLE 20 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR ANTI-ANGIOGENESIS DRUGS , BY REGION, 2018–2032 (USD MILLION) 70 TABLE 21 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR RADIATION THERAPY, BY REGION, 2018–2032 (USD MILLION) 70 TABLE 22 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR SURGERY, BY REGION, 2018–2032 (USD MILLION) 71 TABLE 23 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER, 2018–2032 (USD MILLION) 73 TABLE 24 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2018–2032 (USD MILLION) 74 TABLE 25 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR CANCER RESEARCH CENTERS, BY REGION, 2018–2032 (USD MILLION) 75 TABLE 26 GLOBAL SOFT TISSUE SARCOMA MARKET, FOR OTHERS, BY REGION, 2018–2032 (USD MILLION) 75 TABLE 27 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION, 2018-2032 (USD MILLION) 76 TABLE 28 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018-2032 (USD MILLION) 78 TABLE 29 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 79 TABLE 30 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 79 TABLE 31 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 79 TABLE 32 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 80 TABLE 33 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 80 TABLE 34 US: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 81 TABLE 35 US: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 81 TABLE 36 US: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 81 TABLE 37 US: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 82 TABLE 38 US: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 82 TABLE 39 CANADA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 83 TABLE 40 CANADA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 83 TABLE 41 CANADA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 83 TABLE 42 CANADA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 84 TABLE 43 CANADA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 84 TABLE 44 EUROPE: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018-2032 (USD MILLION) 86 TABLE 45 EUROPE: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 87 TABLE 46 EUROPE: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 87 TABLE 47 EUROPE: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 87 TABLE 48 EUROPE: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 88 TABLE 49 EUROPE: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 88 TABLE 50 GERMANY: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 89 TABLE 51 GERMANY: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 89 TABLE 52 GERMANY: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 89 TABLE 53 GERMANY: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 90 TABLE 54 GERMANY: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 90 TABLE 55 FRANCE: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 91 TABLE 56 FRANCE: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 91 TABLE 57 FRANCE: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 91 TABLE 58 FRANCE: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 92 TABLE 59 FRANCE: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 92 TABLE 60 UK: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 93 TABLE 61 UK: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 93 TABLE 62 UK: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 93 TABLE 63 UK: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 94 TABLE 64 UK: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 94 TABLE 65 ITALY: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 95 TABLE 66 ITALY: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 95 TABLE 67 ITALY: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 95 TABLE 68 ITALY: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 96 TABLE 69 ITALY: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 96 TABLE 70 SPAIN: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 97 TABLE 71 SPAIN: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 97 TABLE 72 SPAIN: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 97 TABLE 73 SPAIN: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 98 TABLE 74 SPAIN: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 98 TABLE 75 RUSSIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 99 TABLE 76 RUSSIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 99 TABLE 77 RUSSIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 99 TABLE 78 RUSSIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 100 TABLE 79 RUSSIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 100 TABLE 80 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 101 TABLE 81 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 101 TABLE 82 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 101 TABLE 83 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 102 TABLE 84 REST OF EUROPE: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 102 TABLE 85 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018-2032 (USD MILLION) 104 TABLE 86 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 105 TABLE 87 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 105 TABLE 88 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 105 TABLE 89 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 106 TABLE 90 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 106 TABLE 91 CHINA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 107 TABLE 92 CHINA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 107 TABLE 93 CHINA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 107 TABLE 94 CHINA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 108 TABLE 95 CHINA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 108 TABLE 96 INDIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 109 TABLE 97 INDIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 109 TABLE 98 INDIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 109 TABLE 99 INDIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 110 TABLE 100 INDIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 110 TABLE 101 JAPAN: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 111 TABLE 102 JAPAN: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 111 TABLE 103 JAPAN: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 111 TABLE 104 JAPAN: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 112 TABLE 105 JAPAN: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 112 TABLE 106 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 113 TABLE 107 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 113 TABLE 108 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 113 TABLE 109 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 114 TABLE 110 SOUTH KOREA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 114 TABLE 111 MALAYSIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 115 TABLE 112 MALAYSIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 115 TABLE 113 MALAYSIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 115 TABLE 114 MALAYSIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 116 TABLE 115 MALAYSIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 116 TABLE 116 THAILAND: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 117 TABLE 117 THAILAND: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 117 TABLE 118 THAILAND: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 117 TABLE 119 THAILAND: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 118 TABLE 120 THAILAND: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 118 TABLE 121 INDONESIA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 119 TABLE 122 INDONESIA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 119 TABLE 123 INDONESIA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 119 TABLE 124 INDONESIA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 120 TABLE 125 INDONESIA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 120 TABLE 126 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 121 TABLE 127 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 121 TABLE 128 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 121 TABLE 129 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 122 TABLE 130 REST OF ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 122 TABLE 131 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018-2032 (USD MILLION) 124 TABLE 132 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 125 TABLE 133 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 125 TABLE 134 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 126 TABLE 135 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 126 TABLE 136 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 127 TABLE 137 BRAZIL: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 127 TABLE 138 BRAZIL: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 127 TABLE 139 BRAZIL: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 128 TABLE 140 BRAZIL: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 128 TABLE 141 BRAZIL: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 128 TABLE 142 MEXICO: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 129 TABLE 143 MEXICO: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 129 TABLE 144 MEXICO: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 129 TABLE 145 MEXICO: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 130 TABLE 146 MEXICO: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 130 TABLE 147 ARGENTINA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 131 TABLE 148 ARGENTINA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 131 TABLE 149 ARGENTINA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 131 TABLE 150 ARGENTINA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 132 TABLE 151 ARGENTINA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 132 TABLE 152 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 133 TABLE 153 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 133 TABLE 154 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 133 TABLE 155 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 134 TABLE 156 REST OF SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 134 TABLE 157 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2018-2032 (USD MILLION) 136 TABLE 158 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 137 TABLE 159 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 138 TABLE 160 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 138 TABLE 161 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 138 TABLE 162 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 139 TABLE 163 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 139 TABLE 164 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 140 TABLE 165 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 140 TABLE 166 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 141 TABLE 167 GCC COUNTRIES: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 141 TABLE 168 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 142 TABLE 169 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 142 TABLE 170 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 142 TABLE 171 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 143 TABLE 172 SOUTH AFRICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 143 TABLE 173 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY TYPE, 2018-2032 (USD MILLION) 144 TABLE 174 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018-2032 (USD MILLION) 144 TABLE 175 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2032 (USD MILLION) 145 TABLE 176 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2032 (USD MILLION) 145 TABLE 177 REST OF MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY END USER, 2018-2032 (USD MILLION) 146 TABLE 178 PUBLIC PLAYERS STOCK SUMMARY 150 TABLE 179 PRODUCT APPROVAL 151 TABLE 180 COLLABORATION 151 TABLE 181 PRODUCT LAUNCH 151 TABLE 182 GE HEALTHCARE: PRODUCTS OFFERED 154 TABLE 183 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED 157 TABLE 184 NOVARTIS AG: PRODUCTS OFFERED 160 TABLE 185 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 164 TABLE 186 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS 164 TABLE 187 BLUEPRINT MEDICINES CORPORATION: PRODUCTS OFFERED 168 TABLE 188 BLUEPRINT MEDICINES CORPORATION: KEY DEVELOPMENTS 169 TABLE 189 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED 171 TABLE 190 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED 174 TABLE 191 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS 175 TABLE 192 EISAI CO., LTD: PRODUCT OFFERED 177 TABLE 193 SIEMENS HEALTHINEERS: PRODUCTS OFFERED 180 TABLE 194 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS 181 TABLE 195 ELI LILLY AND COMPANY: PRODUCTS OFFERED 184 LIST OF FIGURES FIGURE 1 GLOBAL SOFT TISSUE SARCOMA MARKET: STRUCTURE 22 FIGURE 2 GLOBAL SOFT TISSUE SARCOMA MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 38 FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 41 FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 43 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL SOFT TISSUE SARCOMA MARKET 46 FIGURE 6 GLOBAL SOFT TISSUE SARCOMA MARKET, TYPE SEGMENT, 2023 & 2032 (USD MILLION) 58 FIGURE 7 GLOBAL SOFT TISSUE SARCOMA MARKET, BY TYPE, 2023 & 2032 (USD MILLION) 59 FIGURE 8 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY TYPE, 2023 60 FIGURE 9 GLOBAL SOFT TISSUE SARCOMA MARKET, DIAGNOSIS AND TREATMENT SEGMENT, 2023 & 2032 (USD MILLION) 63 FIGURE 10 GLOBAL SOFT TISSUE SARCOMA MARKET, BY DIAGNOSIS AND TREATMENT, 2023 & 2032 (USD MILLION) 64 FIGURE 11 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY DIAGNOSIS AND TREATMENT, 2023 64 FIGURE 12 GLOBAL SOFT TISSUE SARCOMA MARKET, END USER SEGMENT, 2023 & 2032 (USD MILLION) 72 FIGURE 13 GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER, 2023 & 2032 (USD MILLION) 73 FIGURE 14 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY END USER, 2023 74 FIGURE 15 GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION, 2023 & 2032 (USD MILLION) 76 FIGURE 16 GLOBAL SOFT TISSUE SARCOMA MARKET SHARE (%), BY REGION, 2023 77 FIGURE 17 NORTH AMERICA MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018-2032 (USD MILLION) 77 FIGURE 18 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 78 FIGURE 19 NORTH AMERICA: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023 78 FIGURE 20 EUROPE MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018-2032 (USD MILLION) 85 FIGURE 21 EUROPE: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 85 FIGURE 22 EUROPE: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023 86 FIGURE 23 ASIA-PACIFIC MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018-2032 (USD MILLION) 103 FIGURE 24 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 103 FIGURE 25 ASIA-PACIFIC: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023 104 FIGURE 26 SOUTH AMERICA MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018-2032 (USD MILLION) 123 FIGURE 27 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 124 FIGURE 28 SOUTH AMERICA: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023 125 FIGURE 29 MIDDLE EAST AND AFRICA MARKET ANALYSIS: SOFT TISSUE SARCOMA MARKET, 2018-2032 (USD MILLION) 135 FIGURE 30 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION) 136 FIGURE 31 MIDDLE EAST AND AFRICA: SOFT TISSUE SARCOMA MARKET SHARE (%), BY COUNTRY, 2023 137 FIGURE 32 GLOBAL SOFT TISSUE SARCOMA MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 148 FIGURE 33 COMPETITOR DASHBOARD: GLOBAL SOFT TISSUE SARCOMA MARKET 149 FIGURE 34 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT 153 FIGURE 35 GE HEALTHCARE: SWOT ANALYSIS 155 FIGURE 36 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 160 FIGURE 37 NOVARTIS AG: SWOT ANALYSIS 161 FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT 164 FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 165 FIGURE 40 BLUEPRINT MEDICINES CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 168 FIGURE 41 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT 171 FIGURE 42 JOHNSON & JOHNSON INC.: SWOT ANALYSIS 172 FIGURE 43 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT 174 FIGURE 44 EISAI CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 177 FIGURE 45 EISAI CO., LTD.: SWOT ANALYSIS 178 FIGURE 46 SIEMENS HEALTHINEERS: FINANCIAL OVERVIEW SNAPSHOT 180 FIGURE 47 SIEMENS HEALTHINEERS: SWOT ANALYSIS 181 FIGURE 48 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 184

提及公司

GlaxoSmithKline plc (U.K.)Eli Lilly and Company (U.S.)Pfizer Inc. (U.S.)Bristol-Myers Squibb (U.S.)F. Hoffmann-La Roche AG (Genentech) (Switzerland)Johnson & Johnson Services Inc. (U.S.)and others

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們